Position
Scientist, Metabolism
NewLimit
- South San Francisco, United States
- Epigenetics, Cell Biology and
About
NewLimit develops medicines for age-related disease by reprogramming the epigenome to restore regenerative potential in aged and diseased cells, using functional genomics, pooled perturbation screening and machine learning to study epigenetic ageing at scale. The Metabolism team develops reprogramming medicines that restore youthful function in aged hepatocytes in metabolic disease. The scientist designs and tests epigenetic reprogramming interventions for aged and diseased hepatocytes with the single-cell technology, epigenetic editing and predictive modelling teams; develops assays in pre-clinical models of liver disease; delivers reprogramming perturbations to hepatocytes in vivo with viral vectors and lipid nanoparticles; and evaluates payloads to select therapeutic candidates.
The salary range is $130,000–$165,000 USD.
Requirements
Ph.D. in cell biology, molecular biology, biochemistry or a related field, or equivalent industry experience (5+ years); experience isolating and functionally characterising primary liver cells; experience with mouse models of liver dysfunction; experience with transgenic manipulation of liver cells ex vivo or in vivo (for example viral vectors or nucleic-acid delivery); strong organisational and record-keeping skills. Nice to have: pre-clinical or clinical drug development, single-cell genomics and pooled screening (CRISPR, Perturb-seq/CROP-seq).
Topics
- epigenetic reprogramming, search World Wide
- hepatocytes, search World Wide
- lipid nanoparticles, search World Wide
- metabolic disease, search World Wide
- epigenetic ageing, search World Wide
- functional genomics, search World Wide
- pooled perturbation screening, search World Wide
- machine learning, search World Wide
- single-cell technology, search World Wide
- epigenetic editing, search World Wide
Source: NewLimit